Literature DB >> 22236786

Treatment of early Acanthamoeba keratitis with alcohol-assisted epithelial debridement.

Mei-Lun Li1, Min-Hsiu Shih, Fu-Chin Huang, Sung-Huei Tseng, Chien-Chin Chen.   

Abstract

PURPOSE: To study the safety and efficacy of treating early-stage Acanthamoeba keratitis (AK) with 20% alcohol-assisted epithelial debridement.
METHODS: Four consecutive patients (2 wearing orthokeratology lenses and 2 wearing soft contact lenses) presented with pseudodendrites, radial keratoneuritis, and epithelial irregularities. Using a technique similar to laser-assisted subepithelial keratomileusis, we performed alcohol-assisted full-thickness debridement of the corneal epithelium and sent portions for smears, histopathologic and ultrastructural examinations, and culture for evidence of Acanthamoeba. Patients were then started on topical propamidine isethionate and 0.02% polyhexamethylene biguanide.
RESULTS: Immediately after debridement, minimal underlying anterior stromal infiltrate or haze was seen. Dosages of antiamoebic agents were tapered as corneal defects reepithelialized (in 1-3 weeks) with no evidence of post-debridement corneal infection. At the final follow-up, 1 cornea was transparent and the other 3 corneas had very faint subepithelial haze. Cultures of all epithelial debridement specimens yielded Acanthamoeba trophozoites and cysts, and histopathologic and electron microscopic examinations revealed Acanthamoeba organisms within corneal epithelial layers.
CONCLUSIONS: Alcohol-assisted epithelial debridement facilitates detachment of the full-thickness corneal epithelial layer in a controlled manner and seems to be effective in the treatment of early-stage AK. Unlike the fragile fragmented specimens obtained by mechanical scraping without alcohol soaking, epithelial sheets detached easily and the architectures were well preserved, permitting histopathologic and ultrastructural examinations. Most importantly, 20% alcohol-assisted epithelial debridement did not prevent culturing of Acanthamoeba from the removed epithelial specimens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236786     DOI: 10.1097/ICO.0b013e31823f091a

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  6 in total

1.  The effect of the disulfideisomerase domain containing protein in the defense against polyhexamethylene biguanide of highly tolerant Acanthamoeba at the trophozoite stage.

Authors:  Fu-Chin Huang; Tao-Shen Liu; Sung-Chou Li; Min-Hsiu Shih; Jyh-Wei Shin; Wei-Chen Lin
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-11-14       Impact factor: 4.077

2.  Pathogenic Acanthamoeba castellanii Secretes the Extracellular Aminopeptidase M20/M25/M40 Family Protein to Target Cells for Phagocytosis by Disruption.

Authors:  Jian-Ming Huang; Chen-Chieh Liao; Chung-Ching Kuo; Lih-Ren Chen; Lynn L H Huang; Jyh-Wei Shin; Wei-Chen Lin
Journal:  Molecules       Date:  2017-12-18       Impact factor: 4.411

3.  The Biochemical and Functional Characterization of M28 Aminopeptidase Protein Secreted by Acanthamoeba spp. on Host Cell Interaction.

Authors:  Jian-Ming Huang; Yao-Tsung Chang; Wei-Chen Lin
Journal:  Molecules       Date:  2019-12-13       Impact factor: 4.411

4.  Intracellular Microbiome Profiling of the Acanthamoeba Clinical Isolates from Lens Associated Keratitis.

Authors:  Yu-Jen Wang; Sung-Chou Li; Wei-Chen Lin; Fu-Chin Huang
Journal:  Pathogens       Date:  2021-02-25

5.  Cytochrome P450 monooxygenase of Acanthamoeba castellanii participates in resistance to polyhexamethylene biguanide treatment.

Authors:  Jian-Ming Huang; Pin-Ju Ko; Chao-Li Huang; Po-Wei Wen; Chun-Hsien Chen; Min-Hsiu Shih; Wei-Chen Lin; Fu-Chin Huang
Journal:  Parasite       Date:  2021-11-10       Impact factor: 3.000

6.  Effect of ethanol pretreatment in Acanthamoeba keratitis: a long-term follow-up study.

Authors:  I-Huang Lin; Sung-Huei Tseng; Fu-Chin Huang; Yi-Hsun Huang
Journal:  Infect Drug Resist       Date:  2018-07-05       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.